About Origin Life Sciences
Origin Life Sciences is a private company based in Princeton, New Jersey. It has reported $3,042,700 raised in five offerings on Form D since April 2013. Its chief executive is Michael Preston.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2023 | Oct 17, 2023 | $51,000of $5.0M target | 2 | $25,500 | EquityRule 506(b) | Form D ↗ |
| May 30, 2023 | Jun 1, 2023amended Jun 22, 2023 | $659,600of $850K target | 6 | $109K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 30, 2022 | Sep 7, 2022 | $500,000of $5.0M target | 7 | $71,429 | EquityRule 506(b) | Form D ↗ |
| Jan 6, 2017 | May 15, 2017 | $1,332,100of $22.5M target | 32 | $41,628 | EquityRule 506(b) | Form D ↗ |
| Mar 22, 2013 | Apr 8, 2013 | $500,000of $2.5M target | 1 | $500K | Equity06 | Form D ↗ |
| Total, five offerings | $3,042,700 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Origin Life Sciences's Form D filed Oct 17, 2023.
Earlier filings also listed Vic Micati (director, last listed Sep 2022), Mike Pohl (executive officer, last listed Sep 2022), Johnny Fernandes (executive officer, last listed Sep 2022), Howard Nelson (director, last listed Sep 2022), Alex Dolgopolsky, MD (executive officer, last listed Sep 2022), Betsy Hanna (executive officer, last listed May 2017) and Issac Anthony III (executive officer, last listed Apr 2013).